RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 90 - per page Next page
Order by
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Breast Cancer, Lung cancer, Pancreatic caner(cytotoxic chemotheraphy) More
Lotuzol is a new herbal drug composing water extract powder of Nelumbinis Semen to treat depression without sexual dysfunction, a major adverse effect in commonly used anti-depressants. More
KD501 is a partially purified extract from Scrophulariae Radix, which shows an efficacy for the treatment of strokes and degenerated neuronal disease in vivo. Elcom filed an IND application with the KFDA (The Korea Food & Drug Administration) in May More
Production process of C3 synthons by biotransformation. More
Different myeloma tumor cell lines and their expansion for use in drug screening and research More
CG100649 is a lead candidate being developed as osteoarthritis therapeutic and is currently in Phase II clinical stage More
Blood Group Genotyping: Primers for RHD and ABO Gene Amplification More
Development of Corticotropin-Releasing Factor Overproducing Transgenic Mice More
Displaying 1..10 of 90 - per page Next page
Order by

Related Reports

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us